In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):181-185. doi: 10.1016/j.ijrobp.2023.03.065. Epub 2023 Apr 3.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Squamous Cell* / therapy
  • Head
  • Head and Neck Neoplasms* / radiotherapy
  • Humans
  • Ipilimumab / adverse effects
  • Nivolumab / adverse effects
  • Squamous Cell Carcinoma of Head and Neck / drug therapy
  • Squamous Cell Carcinoma of Head and Neck / radiotherapy

Substances

  • Nivolumab
  • Ipilimumab

Associated data

  • ClinicalTrials.gov/NCT03162731